On this page
- Anthelminthic (antifilarial)
- Lymphatic filariasis
Forms and strengths
- 100 mg breakable tablet
- Child under 10 years: 0.5 mg/kg on D1, then increase the dose gradually over 3 days to 1 mg/kg 3 times daily
- Child over 10 years and adult: 1 mg/kg on D1, then increase the dose gradually over 3 days to 2 mg/kg 3 times daily
- W. bancrofti: 12 days
- B. malayi, B. timori: 6 to 12 days
Contra-indications, adverse effects, precautions
- Do not administer to patients with onchocerciasis or heavy Loa loa microfilareamia; to infants, elderly patients and patients with heart or renal diseases.
- Do not administer during acute attacks (risk of severe reactions).
- Administer with caution in patients with history of seizures.
- May cause:
- nausea, vomiting, headache, dizziness, drowsiness, fever, joint pain, urticaria, transient haematuria, subcutaneous nodules, lymphangitis, localized oedema;
- in patients with associated onchocerciasis: severe ocular damages (optic nerve lesions, retinal lesions);
- in patients with associated loiasis: encephalitis (potentially fatal) if Loa loa microfilaraemia is high.
- Reduce dosage in patients with renal impairment.
- Pregnancy: CONTRA-INDICATED (treatment may be deferred until after delivery)
- Breast-feeding: not recommended
- In countries with a national programme for the elimination of bancroftian filariasis, the combination diethylcarbamazine + albendazole is administered as a single annual dose for 4 to 6 years. This regimen is only suitable for countries that are free from Onchocerca volvulus and/or Loa loa.
- Diethylcarbamazine is included in the WHO complementary list of essential medicines.
- Between 15 °C and 25 °C